Literature DB >> 10192876

Homing mechanisms of myeloma cells.

I Van Riet1.   

Abstract

A stricking feature of myeloma plasma cells concerns their tendency to reside in the bone marrow compartment during the main course of the disease evolution. This micro-environment provides the appropriate signals for growth and survival of the tumor cells. Since small amounts of myeloma cells are also detectable in the peripheral blood, it can be assumed that these cells represent lymph node and/or bone marrow derived tumor cells that directly contribute to disease spreading. The detection of such myeloma-related cells in the circulation implicates that they must be equipped with the appropriate surface molecules that mediate binding to endothelium, responsiveness to chemokines, transendothelial migration and extravasation. The specificity of this migration process might be a second important factor that determines the selective homing of myeloma cells in the marrow-microenvironment. During the end phase of the disease, increasing numbers of myeloma cells become detectable in the blood circulation and also extramedulary tumor localisation at other sites (liver, lung, ascites and pleural fluid) can occur. Molecular evolution towards stroma-independency in association with an enhanced extravasation potential are likely to be the key mechanisms that underlie this disturbed homing behaviour.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10192876

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  5 in total

1.  Small hepatic vein involvement in IgG multiple myeloma: a very unusual pattern of liver infiltration.

Authors:  Thierry Lazure; Corinne Miceli-Richard; Jérémie Sellam; Monique Fabre; Xavier Mariette; Catherine Guettier
Journal:  Virchows Arch       Date:  2006-11-17       Impact factor: 4.064

Review 2.  Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.

Authors:  D Atanackovic; T Luetkens; N Kröger
Journal:  Leukemia       Date:  2013-10-23       Impact factor: 11.528

3.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

Authors:  R N Pearse; E M Sordillo; S Yaccoby; B R Wong; D F Liau; N Colman; J Michaeli; J Epstein; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

Review 4.  Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.

Authors:  Caterina Musolino; Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2017-09-26       Impact factor: 4.711

Review 5.  Extramedullary myeloma in an HIV-seropositive subject. Literature review and report of an unusual case.

Authors:  Liviu Feller; Jason White; Neil H Wood; Michael Bouckaert; Johan Lemmer; Erich J Raubenheimer
Journal:  Head Face Med       Date:  2009-01-20       Impact factor: 2.151

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.